← All trials
NCT00487799
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2007
- Primary completion
- —
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 32
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Facet BiotechLead sponsor
- Henry Ford Health SystemOverall official - principal investigator
- Cardiovascular Specialists PC dba New York Heart CtrOverall official - principal investigator
- Kore Cardiovascular Research InstituteOverall official - principal investigator
- The Atlanta Cardiology Group, PCOverall official - principal investigator
- Northwestern UniversityOverall official - principal investigator
- University of California, San DiegoOverall official - principal investigator
- Yeshiva UniversityOverall official - principal investigator
- Washington University in St. LouisOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.